Signal transducers and activators of transcription 3 function in lung cancer

Journal of Cancer Research and Therapeutics

Volumn 9, Issue SUPPL. 2, 2013, Pages

  Li, Chun Jie ^a,c   Li, Yue Chuan ^b   Zhang, Dong Rui ^b   Pan, Jian Hui ^b  

^a Department of Cardiology ^*  (China)

^b TIANJIN CHEST HOSPITAL   (China)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cell competition; epidermal growth factor receptor; lung cancer; signal transducers and activators of transcription 3

Indexed keywords

STAT3 PROTEIN;

CANCER GROWTH; CELL FUNCTION; CELLULAR PARAMETERS; HUMAN; INFLAMMATION; LUNG CANCER; LUNG CARCINOGENESIS; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84885616721     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.119100     Document Type: Review

References (85)

1. Zupa A, Improta G, Silvestri A, Pin E, Deng J, Aieta M, et al. A pilot characterization of human lung NSCLC by protein pathway activation mapping. J Thorac Oncol 2012;7:1755-66.
2. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-34.
3. Okada H, Anayama T, Kume M, Hirohashi K, Miyazaki R, Matsumoto M, et al. Comparison of epidermal growth factor receptor mutation analysis results between surgically resected primary lung cancer and metastatic lymph nodes obtained by endobronchial ultrasoundguided transbronchial needle aspiration. Thorac Cancer 2012;3:262-8.
4. Huang Z, Wang Z, Bai H, Wu MN, An TT, Zhao J, et al. The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thorac Cancer 2012;3:334-40.
5. Zhang XH, Li C, Dai CF, Zhou BS. Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis. Thorac Cancer 2011;2:101-8.
6. Wieczorek M, Ginter T, Brand P, Heinzel T, Krämer OH. Acetylation modulates the STAT signaling code. Cytokine Growth Factor Rev 2012;23:293-305.
7. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005;24:3397-408.
8. Lim CP, Cao X. Structure, function, and regulation of STAT proteins. Mol Biosyst 2006;2:536-50.
9. Brzezianska E, Domanska D. Review: The JAK/STAT protein activation-Role in cancer development and targeted therapy. Curr Signal Transduct Ther 2012;7:187-201.
10. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-86.
11. Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, et al. Gene expression profiling in acute allograft rejection: Challenging the immunologic constant of rejection hypothesis. J Transl Med 2011;9:174.
12. Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 2011;10:481-94.
13. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513.
14. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005;7:545-55.
15. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 2004;3:11-20.
16. Tu B, Du L, Fan QM, Tang Z, Tang TT. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett 2012;325:80-8.
17. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905-13.
18. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008;111:1515-23.
19. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2006;66:3188-96.
20. Chiu HC, Chou DL, Huang CT, Lin WH, Lien TW, Yen KJ, et al. Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. Biochem Pharmacol 2011;81:1263-70.
21. Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res 2008;18:443-51.
22. Lane ML, Frost CD, Nguyen JP, Skelton WP 4th, Skelton M, Vesely DL. Potent selective inhibition of STAT 3 versus STAT 1 by cardiac hormones. Mol Cell Biochem 2012;371:209-15.
23. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, et al. Inflammation and lung carcinogenesis: Applying findings in prevention and treatment. Expert Rev Anticancer Ther 2007;7:1405-21.
24. Bronte-Tinkew DM, Terebiznik M, Franco A, Ang M, Ahn D, Mimuro H, et al. Helicobacter pylori cytotoxin-associated gene A activates the signal transducer and activator of transcription 3 pathway in vitro and in vivo. Cancer Res 2009;69:632-9.
25. Landen CN Jr, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, et al. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 2007;67:10389-96.
26. Aziz MH, Manoharan HT, Verma AK. Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res 2007;67:1385-94.
27. Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA. Receptor-mediated tobacco toxicity: Cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J 2006;20:2093-101.
28. Yu B, Huang L, Tiwari RC, Feuer EJ, Johnson KA. Modelling population-based cancer survival trends using join point models for grouped survival data. J R Stat Soc Ser A Stat Soc 2009;172:405-25.
29. Yang J, Liao D, Chen C, Liu Y, Chuang TH, Xiang R, et al. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 2013;31:248-58.
30. Peng Q, Li M, Wang Z, Jiang M, Yan X, Lei S, et al. Polarization of tumor-associated macrophage is associated with tumor vascular normalization by endostatin. Thorac Cancer 2013; 4:295-305.
31. Bansa A. Cancer stem cells in the origin and transformation of Barrett's esophagus: Current knowledge and areas of uncertainty. Immunogastroenterology 2013;2:9.
32. Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 2006;12:4288-93.
33. Liu L, Wang J, Shi L, Zhang W, Du X, Wang Z, et al. -Asarone induces senescence in colorectal cancer cells by® inducing lamin B1 expression. Phytomedicine 2013;20:512-20.
34. Tannenbaum CS, Hamilton TA. Immune-inflammatory mechanisms in IFNgamma-mediated anti-tumor activity. Semin Cancer Biol 2000;10:113-23.
35. Wang M, Liang P. Interleukin-24 and its receptors. Immunology 2005;114:166-70.
36. Tanabe T, Fujimoto K, Yasuo M, Tsushima K, Yoshida K, Ise H, et al. Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium. Clin Exp Allergy 2008;38:122-34.
37. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006;12:11-9.
38. Samavati L, Rastogi R, Du W, Hüttemann M, Fite A, Franchi L. STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria. Mol Immunol 2009;46:1867-77.
39. Ravichandran K, Tyagi A, Deep G, Agarwal C, Agarwal R. Interleukin-1beta-induced iNOS expression in human lung carcinoma A549 cells: Involvement of STAT and MAPK pathways. Indian J Exp Biol 2011;49:840-7.
40. Park JI, Strock CJ, Ball DW, Nelkin BD. Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine 2005;29:125-34.
41. Peuckmann V, Ekholm O, Rasmussen NK, Groenvold M, Christiansen P, Møller S, et al. Chronic pain and other sequelae in long-term breast cancer survivors: Nationwide survey in Denmark. Eur J Pain 2009;13:478-85.
42. Velichko S, Wagner TC, Turkson J, Jove R, Croze E. STAT3 activation by type I interferons is dependent on specific tyrosines located in the cytoplasmic domain of interferon receptor chain 2c. Activation of multiple STATS proceeds through the redundant usage of two tyrosine residues. J Biol Chem 2002;277:35635-41.
43. Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res 2011;31:33-40.
44. Chim CS, Wong AS, Kwong YL. Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias. Ann Hematol 2004;83:527-32.
45. Lin YC, Lin CK, Tsai YH, Weng HH, Li YC, You L, et al. Adenovirus-mediated SOCS3 gene transfer inhibits the growth and enhances the radiosensitivity of human non-small cell lung cancer cells. Oncol Rep 2010;24:1605-12.
46. Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez JJ, et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst 2011;103:1552-6.
47. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 2012;109:9623-8.
48. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-65.
49. Quesnelle KM, Boehm AL, Grandis Jr. STAT-mediated EGFR signaling in cancer. J Cell Biochem 2007;102:311-9.
50. Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005;11:8288-94.
51. Baykara O, Tansarikaya M, Demirkaya A, Kaynak K, Tanju S, Toker A, et al. Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients. Exp Ther Med 2013;5:495-8.
52. Zhao W, Jaganathan S, Turkson J. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem 2010;285:35855-65.
53. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66:5542-8.
54. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005;2:e313.
55. Yang S, Park K, Turkson J, Arteaga CL. Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. Exp Cell Res 2008;314:413-9.
56. Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 2005;65:8968-74.
57. Jiang R, Jin Z, Liu Z, Sun L, Wang L, Li K. Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Mol Diagn Ther 2011;15:347-52.
58. Dobashi Y, Suzuki S, Sugawara H, Ooi A. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors. Hum Pathol 2007;38:914-25.
59. van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G. Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 2009;9:180.
60. Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches. Drug Resist Updat 2010;13:67-78.
61. Kannangai R, Sahin F, Torbenson MS. EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol 2006;19:1456-61.
62. Huang WL, Yeh HH, Lin CC, Lai WW, Chang JY, Chang WT, et al. Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: A biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells. Mol Cancer 2010;9:309.
63. Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 2004;60:303-9.
64. Kaymaz BT, Selvi N, Saydam G, Sahin F, Kosova B. Methylprednisolone induces apoptosis by interacting with the JAK/STAT pathway in HL-60 and K-562 leukemic cells. Hematology 2012;17:93-9.
65. Zhao M, Jiang B, Gao FH. Small molecule inhibitors of STAT3 for cancer therapy. Curr Med Chem 2011;18:4012-8.
66. Jing N, Sha W, Li Y, Xiong W, Tweardy DJ. Rational drug design of G-quartet DNA as anti-cancer agents. Curr Pharm Des 2005;11:2841-54.
67. Weerasinghe P, Garcia GE, Zhu Q, Yuan P, Feng L, Mao L, et al. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol 2007;31:129-36.
68. Qian X, Ren Y, Shi Z, Long L, Pu P, Sheng J, et al. Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. Mol Pharm 2012;9:2636-45.
69. Gao W, Xu J, Liu L, Shen H, Zeng H, Shu Y. A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother 2012;66:21-8.
70. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 2012;31:3513-23.
71. Yan H. Interleukin-17F: A promising candidate of cancer therapy. Immunogastroenterology 2012;1:100.
72. Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, et al. miR-17-92 expression in differentiated T cells-implications for cancer immunotherapy. J Transl Med 2010;8:17.
73. Matsuyama H, Suzuki HI, Nishimori H, Noguchi M, Yao T, Komatsu N, et al. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood 2011;118:6881-92.
74. In press.
75. Makowjecki C, Nolte A, Sutai B, Keller T, Avci-Adali M, Stoll H, et al. New basic approach to treat non-small-cell-lung-cancer based on RNA-Interference. Thorac Cancer 2013; In press. 75. Dunlap N, McIntosh A, Sheng K, Yang W, Turner B, Shoushtari A, et al. Helical tomotherapy-based STAT stereotactic body radiation therapy: Dosimetric evaluation for a real-time SBRT treatment planning and delivery program. Med Dosim 2010;35:312-9.
76. Hu X, Dutta P, Tsurumi A, Li J, Wang J, Land H, et al. Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth. Proc Natl Acad Sci U S A 2013;110:10213-8.
77. Chen X, Du Y, Nan J, Zhang X, Qin X, Wang Y, et al. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS One 2013;8:e63697.
78. Carmo CR, Lyons-Lewis J, Seckl MJ, Costa-Pereira AP. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells. PLoS One 2011;6:e19861.
79. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63:1270-9.
80. Ren Z, Schaefer TS. ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. J Biol Chem 2002;277:38486-93.
81. Ecker A, Simma O, Hoelbl A, Kenner L, Beug H, Moriggl R, et al. The dark and the bright side of Stat3: Proto-oncogene and tumor-suppressor. Front Biosci (Landmark Ed) 2009;14:2944-58.
82. Levayer R, Moreno E. Mechanisms of cell competition: Themes and variations. J Cell Biol 2013;200:689-98.
83. Arbouzova NI, Zeidler MP. JAK/STAT signalling in Drosophila: Insights into conserved regulatory and cellular functions. Development 2006;133:2605-16.
84. Li Q, Zhang R, Guo YL, Mei YW. Effect of neuregulin on apoptosis and expressions of STAT3 and GFAP in rats following cerebral ischemic reperfusion. J Mol Neurosci 2009;37:67-73.
85. Rodrigues AB, Zoranovic T, Ayala-Camargo A, Grewal S, Reyes-Robles T, Krasny M, et al. Activated STAT regulates growth and induces competitive interactions independently of Myc, Yorkie, Wingless and ribosome biogenesis. Development 2012;139:4051-61.